S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
S&P 500   4,967.23 (-0.88%)
DOW   37,986.40 (+0.56%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
ASX:RAD

Radiopharm Theranostics (RAD) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)
Free RAD Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
RAD stock logo

About Radiopharm Theranostics Stock (ASX:RAD)

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It is developing its lead products comprising Nano-mAbs and AVB6 Integrin. The company was incorporated in 2021 and is based in Carlton, Australia.

RAD Stock News Headlines

April 10, 2024 | msn.com
Lisata wins FDA orphan drug status for bone cancer candidate
April 9, 2024 | msn.com
Radiopharmaceutical emerges as the hottest space in biotech; here’s what it means for Clarity Pharma
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
March 16, 2024 | morningstar.com
Radiopharm Theranostics Ltd Ordinary Shares
February 25, 2024 | msn.com
Radiopharmaceutical market expected to reach ~$14B by 2032
February 13, 2024 | uk.finance.yahoo.com
Radiopharm Theranostics Limited (RDPTF)
February 5, 2024 | au.investing.com
Radiopharm Theranostics' novel monoclonal antibody shows promise in cancer treatment
January 26, 2024 | au.investing.com
Radiopharm Theranostics completes entitlement offer shortfall for $1.7 million
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
January 20, 2024 | morningstar.com
Radiopharm Theranostics Ltd Ordinary Shares RAD
December 27, 2023 | au.investing.com
Radiopharm Theranostics to open second Australian site for lung cancer trial
December 22, 2023 | au.investing.com
Radiopharm Theranostics launching Phase 1 lung cancer trials in January
November 20, 2023 | au.investing.com
Radiopharm Theranostics' $4.85 million R&D refund will support development of radiopharmaceutical products
October 30, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics launches $10 million entitlement offer to fund clinical trials
October 16, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics receives FDA greenlight to start Phase 1 imaging trial of RAD 301
October 9, 2023 | finance.yahoo.com
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
October 9, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics secures approval for Phase 1 PDL1-nanobody non-small cell lung cancer study
September 1, 2023 | finance.yahoo.com
Radiopharm Theranostics Full Year 2023 Earnings: AU$0.11 loss per share (vs AU$0.17 loss in FY 2022)
August 24, 2023 | finance.yahoo.com
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
August 24, 2023 | proactiveinvestors.com
Radiopharm Theranostics expands TerThera supply agreement for prostate cancer treatment trial
July 24, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics appoints experienced radiopharmaceutical developer as VP Medical and Corporate Affairs
July 23, 2023 | finance.yahoo.com
Theradiag Reports Revenue of €6.7 Million for the First Half of 2023, up 6.8%
July 19, 2023 | finance.yahoo.com
Is Radiopharm Theranostics (ASX:RAD) In A Good Position To Invest In Growth?
June 23, 2023 | marketwatch.com
Radiopharmaceuticals Global Market is Projected to Reach $12.6 Billion by 2030: Innovative Radiopharmaceuticals to Boost Cardiac Applications
June 9, 2023 | finance.yahoo.com
Diamond Equity Research to Host Global Select Emerging Growth Invitational Virtual Investor Conference on June 13th, 2023
June 6, 2023 | proactiveinvestors.com.au
Radiopharm Theranostics maintains A$0.70 valuation from Diamond Equity Research
May 31, 2023 | proactiveinvestors.com.au
Radiopharm welcomes positive guidance from FDA to advance Pivalate
See More Headlines
Receive RAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radiopharm Theranostics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:RAD
CUSIP
N/A
CIK
N/A
Web
www.riteaid.com
Phone
17177612633
Fax
N/A
Employees
2,021
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.14)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-46,820,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-107.05%
Return on Assets
-30.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.50
Quick Ratio
3.43

Sales & Book Value

Annual Sales
$6.01 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
A$0.06 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
445,130,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.96
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Paul Edward-Alexander Hopper A.S.i.A (Age 68)
    B.A (UNSW), FAICD, Founder & Executive Chairman
    Comp: $271.45k
  • Mr. Riccardo Canevari
    MD, CEO & Director
  • Mr. Vittorio Puppo M.D.
    Chief Operating Officer
  • Prof. David Mozley
    Chief Medical Officer & Scientific Advisory Board Chair
  • Dr. Thomas H. Tulip Ph.D. (Age 71)
    Chief Business Officer
    Comp: $504.74k
  • Mr. Phillip Hains
    CFO & Company Secretary
  • Dr. Scot L. Harper Ph.D. (Age 67)
    Senior Vice President of Clinical Operations
  • Mr. Bill Regan
    Senior Vice President of Regulatory Strategy
  • Dr. Rama Abu Shmeis
    Senior VP of Chemistry, Manufacturing & Controls
  • Mr. Nathan Jong C.A.
    Company Secretary

Key Competitors

View All Competitors

Insiders


This page (ASX:RAD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media